Imaging as a surrogate marker of drug efficacy in cardiovascular disease

Citation for published version:
Tarkin, JM, Dweck, M & Rudd, JH 2018, 'Imaging as a surrogate marker of drug efficacy in cardiovascular disease' Heart. DOI: 10.1136/heartjnl-2017-311213

Digital Object Identifier (DOI):
10.1136/heartjnl-2017-311213

Link:
Link to publication record in Edinburgh Research Explorer

Document Version:
Publisher's PDF, also known as Version of record

Published In:
Heart

General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.
Imaging as a surrogate marker of drug efficacy in cardiovascular disease

Jason M Tarkin,1,2 Marc R Dweck,3 James H F Rudd1

INTRODUCTION
Many cardiovascular drugs in the pipeline will fail to demonstrate a clear clinical benefit when evaluated in large-scale clinical outcome trials, which are costly, require lengthy follow-up and can potentially expose patients to unforeseen risks. There exists an enormous gap between early mechanistic studies demonstrating proof-of-principle drug efficacy in preclinical models and successful translation of these therapies into everyday clinical practice. To help overcome this challenge, cardiovascular imaging techniques can be applied to quantify early changes in disease severity owing to drug intervention, or lack thereof, with the aim of informing subsequent clinical outcome trials. This approach can be used to directly val...

Learning objectives
- Learn how imaging can be applied to gain early insights into drug efficacy and inform the design of phase III clinical outcome trials in cardiovascular disease.
- Understand which markers of atherosclerotic disease severity are most useful as imaging endpoints in drug intervention studies.
- Learn about the emerging role for molecular imaging of inflammation and disease activity in cardiovascular drug development.

Validation of imaging for risk prediction
 Among the most widely used imaging endpoints for cardiovascular drug trials are arterial inflammation, vascular intima media thickness (IMT), plaque burden (or atheroma volume) and plaque morphology.

Vascular inflammation is the earliest modifiable link between clinical cardiovascular risk factors and disease activity that can be detected using imaging. When imaged using 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET), arterial inflammation can offer prognostic information beyond clinical risk factors, including Framingham risk score, with an increased HR of 2.9–4.7 for the highest risk groups in large retrospective analyses.4 IMT provides a measure of local atherosclerotic burden, including early subclinical disease, which has also been correlated with risk of future myocardial infarction (MI) and stroke.5,6 However, the link between vascular IMT and future cardiovascular risk remains unproven,7 and carotid IMT might represent vascular changes arising from arterial hypertension rather than a direct marker of atherosclerosis per se.8 Total plaque burden is in fact the strongest prognostic indicator that has been identified in large prospective imaging trials.9–11 While the presence

© Author(s) (or their employer(s)) 2018. Re-use permitted under CC BY Published by BMJ.

To cite: Tarkin JM, Dweck MR, Rudd JHF. Heart Epub ahead of print: [please include Day Month Year]. doi:10.1136/heartjnl-2017-311213

© BMJ Publishing Group Ltd 2018

BMJ

Tarkin JM, et al. Heart 2018;0:1–12. doi:10.1136/heartjnl-2017-311213
of high-risk plaque features associated with the histological appearance of ‘vulnerable’ rupture-prone thin-cap fibroatheromas (TCFAs) are also predictors of major adverse cardiovascular events (MACE). It remains unclear whether identifying individual plaque characteristics is of incremental value to simpler assessments of plaque burden, as at the plaque level, this approach is limited by poor positive predictive value. Indeed, the vast majority of coronary artery TCFAs identified using virtual histology (VH)-intravascular ultrasound (IVUS) do not go on to cause clinical events because they either heal or rupture silently without clinical sequelae.

New imaging techniques may offer opportunities to measure plaque lipid content, both invasively using near infrared spectroscopy and non-invasively using carotid MRI with T2 mapping. Quantification of pericoronary adipocyte content and inflammation could provide additional surrogate markers of cardiovascular risk for use in clinical drugs trials in the future.

Degree of intraluminal stenosis, ischaemic burden and coronary artery calcification (CAC) are additional imaging markers that have been tested as surrogate endpoints in drug trials. While angiographic stenosis severity and functional ischaemia are among the most important factors used to guide everyday clinical management decisions, particularly when contemplating coronary revascularisation, they represent a late stage in the disease process that is not easily modifiable by drug intervention. Moreover, although there is a well-established association between ‘flow-limiting’ coronary disease and hard clinical outcomes, this relationship might not be causal. Indeed, reversal of coronary ischaemia with drug intervention and percutaneous coronary stenting in patients with stable angina does not appear to reduce rates of long-term MI or death. The presence of haemodynamically obstructive coronary stenoses might instead simply act as a surrogate of plaque burden. CAC scoring is another clinical risk stratification tool that provides an estimate of overall coronary atherosclerotic burden (including the burden of less stable plaques), with strong incremental link to clinical outcomes. However, the clinical significance of change in coronary calcification owing to drug intervention has yet to undergo specific validation as a prognostic biomarker and increases in coronary artery macrocalcification as observed in patients treated with statins might, in fact, be protective rather than harmful.

Other considerations
It is important to acknowledge that any perceived prognostic benefit of surrogate imaging markers, which has been inferred from observational studies, cannot stand alone for drug approval. Moreover, this approach does not account for the influence of confounding factors, including multiple drug effects and cannot replace the need for a prospective controlled clinical trial to test drug safety.

Exposure to ionising radiation, additional risks associated with invasive imaging procedures and local accessibility to imaging technology are other factors to consider when choosing between surrogate imaging endpoints for cardiovascular drug trials. While plaque volume and composition can be more precisely quantified using invasive versus non-invasive coronary imaging, it is worth bearing in mind that there is also a high ~25% participant dropout in contemporary invasive imaging studies. In addition, the concept of an overall ‘barometer’ of disease severity that might be modifiable with drug intervention can be more readily attained using non-invasive than invasive imaging, for example, with PET or MRI, where the entire vascular bed can be imaged simultaneously.

**USE OF IMAGING FOR TESTING DRUG EFFICACY IN ATHEROSCLEROSIS**

Here we discuss how various imaging biomarkers have been applied in clinical drug trials to study the efficacy of disease modifying therapies in atherosclerosis, including both long-established and newly tested lipid-lowering and anti-inflammatory agents.

**Lipid-lowering and other drugs affecting cholesterol**

**Statins**

Statins reduce low-density lipoprotein cholesterol (LDL-c) through inhibition of \( \beta \)-hydroxy \( \beta \)-methylglutaryl-CoA (HMG-CoA) reductase and have been proven in landmark clinical trials to dramatically reduce the incidence of cardiovascular events in a range of individuals, with greater benefit seen for intensive versus moderate or low-dose therapy in patients with stable angina or previous MI. In fact, patients treated with statins who achieve LDL-c lowering of 2–3 mmol/L are expected to have a 40%–50% reduction in cardiovascular risk regardless of their baseline lipid profile. While the clinical benefits of statins have long been proven, contemporary imaging studies have nonetheless contributed important mechanistic insights revealing the multiple effects of statins on the arterial wall and atherosclerotic plaques. Collectively, these studies have demonstrated that treatment with statins can result in reduction of arterial inflammation, IMT, plaque volume and lipid content of the necrotic core, as well as a modest increase in angiographic luminal diameter and increased fibrous cap thickness and arterial macrocalcification contributing to plaque stability.

Dampening of arterial inflammation has been demonstrated in several studies of statins using 18F-FDG PET and ultrasmall superparamagnetic iron oxide (USPIO) nanoparticle-enhanced MRI. For example, ~11% reduction in the inflammatory 18F-FDG PET signal was observed in a study of statin-naïve patients treated with high-intensity atorvastatin after 12 weeks. Statin-induced dampening of arterial inflammation measured by 18F-FDG PET is associated with increases in...
high-density lipoprotein cholesterol (HDL-c) and the inflammatory biomarker matrix metalloproteinase-9. In the Atorvastatin Therapy: Effects on Reduction of Macrophage Activity study, significant reductions in carotid artery inflammation were also found using USPIO-enhanced MRI in patients treated with high-intensity statins. In the Atorvastatin Therapy: Effects on Reduction of Macrophage Activity study, significant reductions in carotid artery inflammation were also found using USPIO-enhanced MRI in patients treated with high-intensity statins.

Regression of arterial IMT has been reliably observed in statin trials. In the Regression Growth Evaluation Statin study, treatment with pravastatin resulted in significant reduction in carotid and femoral IMT measured by B-mode ultrasound in patients with coronary artery disease. Similarly, the randomised placebo controlled Measuring Effects on Intima-Media Thickness: an Evaluation of Rosuvastatin study of 984 middle-aged individuals with low Framingham risk scores but evidence of subclinical atherosclerosis showed a reduction in ultrasound measured carotid IMT after treatment with rosuvastatin. Moreover, the beneficial effect of statins on IMT has also been demonstrated in several studies using MRI of the carotid arteries and the aorta, which also suggested that this drug therapy induces vascular remodelling by reducing atherosclerotic burden without affecting the lumen.

Reduction in coronary artery plaque burden following treatment with statins has been demonstrated by numerous clinical studies using IVUS. Among the many longitudinal IVUS studies undertaken to investigate the effects of statins on coronary artery atherosclerosis are A Study to Evaluate the Effect of Rosuvastatin on Intravascular Ultrasound-Derived Coronary Atheroma Burden (ASTEROID), Reversal of Atherosclerosis with Aggressive Lipid Lowering, Early Statin Treatment in Patients With Acute Coronary Syndrome, Integrated Biomarkers and Imaging Study-4 and Study of Coronary Atheroma by Intravascular Ultrasound: Effect of Rosuvastatin vs. Atorvastatin. Overall, these studies showed that high-intensity statin therapy is associated with significant reduction in percentage atheroma volume irrespective of baseline LDL-c or high-sensitivity C-reactive protein (hsCRP) levels. Moreover, a study including IVUS data from 4477 patients with stable angina demonstrated that individuals with high-risk plaques had accelerated progression of atheroma burden, which was modifiable in patients taking statins.

Numerous imaging studies have shown that statins also induce favourable effects on plaque morphology. For example, in a study of 33 patients imaged using carotid MRI with follow-up over 3 years, significant reductions of lipid-rich necrotic core were observed in patients treated with intensive lipid-lowering including atorvastatin. Other studies using MRI have confirmed reductions in carotid plaque lipid-rich necrotic core and aortic plaque volume with rosuvastatin. High-intensity statin treatment was also associated with a reduction in coronary plaque necrotic core volume and number of TCFAs identified using VH-IVUS in several drug trials, including the Statin and Atheroma Vulnerability Evaluation study. Several trials have evaluated the effects of statins on fibrous cap thickness using optical coherence tomography (OCT). In the Effect of Atorvastatin on Fibrous Cap Thickness on Coronary Atherosclerotic Plaque as Assessed by Optical Coherence Tomography study, increased fibrous cap thickness measured by OCT occurred in correlation to reductions in LDL-c, inflammatory biomarkers and OCT-defined macrophage content. In other OCT studies, patients treated...
with high-intensity statins had smaller lipid arcs and greater fibrous cap thickness compared with those on lower dose or no statins.\textsuperscript{45,46} Significant regression of coronary plaque lipid core content following treatment with rosuvastatin was also seen in the Reduction in Yellow Plaque by Aggressive Lipid lowering therapy (YELLOW) study using near infrared spectroscopy.\textsuperscript{47}

Angiographic measurement of luminal narrowing has also been tested as a surrogate marker in drug trials evaluating the effects of statins. In the Multi-centre Anti-Atheroma Study (MAAS) trial, simvastatin resulted in a 2.6% increase in mean luminal diameter compared with placebo, with less patients showing angiographic disease progression in the treatment group.\textsuperscript{48} However, this surrogate marker was not correlated with extent of LDL-c change, and there was no difference in clinical outcomes between groups after 4 years. In a predefined substudy of the ASTEROID trial, a $-1\%$ reduction in mean per cent diameter stenosis was observed using quantitative IVUS in patients treated with high-dose rosuvastatin, despite $>50\%$ reduction in LDL-c.\textsuperscript{49}

Studies using serial CT coronary angiography (CTCA) scanning have also shown that statins can slow progression of low attenuation and non-calcified plaques in patients with stable coronary disease.\textsuperscript{50,51} Indeed, the Attempts at Plaque Vulnerability Quantification with Magnetic Resonance Imaging Using Noncontrast T1-weighted Technique pilot study showed significant reduction in low attenuation plaque volume and percentage total atheroma volume measured by CTCA, as well as decreased plaque to myocardial signal intensity on T1-weighted MRI (a marker of high-risk plaque).

Figure 2  OCT imaging of fibrous cap thickening after statin treatment. (A) Graph showing per cent change in fibrous cap thickness and lipid arc measured by OCT in a study of 60 patients with unstable angina treated with atorvastatin 20 mg (red) or 5 mg (blue) for 12 months; representative OCT images from this study at (B) baseline and (C) 12 months showing increased fibrous cap thickness after treatment with atorvastatin. Figure adapted from Komukai et al. \textit{J Am Coll Cardiol} 2014.\textsuperscript{46} OCT, optical coherence tomography.
following 12 months of treatment with statins (figure 3). However, in a randomised, double-blind, multicentre trial including 471 patients with moderate CAC and without high-grade stenoses, statins were not able to attenuate progression of coronary artery macrocalcification. In fact, a paradoxical increase in dense calcific density has been observed using CTCA in patients treated with high-intensity rosuvastatin after acute MI. This finding has been confirmed by a post hoc analysis of IVUS data from eight prospective randomised trials including 3495 patients, which showed increased plaque calcification following treatment with statins.

**Ezetimibe**

As a second-line therapy for patients who are intolerant of statins or unable to achieve sufficient LDL-c reduction with statins alone, ezetimibe lowers LDL-c by reducing intestinal absorption of cholesterol. Ezetimibe has been shown to reduce cardiac events by a modest 2% compared with placebo when added to simvastatin in patients with acute coronary syndrome. This relatively small prognostic benefit compared with the large benefit afforded by statins might explain why imaging studies performed in patients treated with ezetimibe have shown somewhat mixed results.

In the Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression and Stop Atherosclerosis in Native Diabetics studies, ezetimibe did not significantly reduce carotid IMT when added to statins in patients with familial hypercholesterolaemia or diabetes mellitus, respectively, despite additional LDL-c lowering. While in the Plaque Regression With Cholesterol Absorption Inhibitor or Synthesis Inhibitor Evaluated by Intravascular Ultrasound study, the combination of high-dose atorvastatin plus ezetimibe resulted in greater regression in atheroma volume determined by IVUS than statins alone (figure 4), this difference failed to meet the predefined non-inferiority margin of 3%. In contrast, another study showed that the addition of ezetimibe to fluvastatin resulted in significantly reduced lipid arc and increased fibrous cap thickness by ~0.04 mm measured using OCT.

Evidence from clinical trials using intravascular imaging also suggests that treatment with ezetimibe does not significantly alter plaque composition when added to statin therapy, despite additional reductions in LDL-c and plaque volume. Both the Virtual Histology of Atherosclerosis Regression During Atorvastatin and Ezetimibe Administration and Effect of Ezetimibe on Stabilization and Regression of Intracoronary Plaque studies showed no significant differences in plaque composition and stabilisation between patients randomised to statin plus ezetimibe versus standard therapy, or statin monotherapy, using serial IVUS imaging over the duration of these studies.

**Other drugs affecting cholesterol**

Other cholesterol-modifying therapies tested using surrogate imaging markers include niacin and cholesteryl ester transfer protein (CETP) inhibitors (eg, dalcetrapib). While these studies mostly showed little or no beneficial effect on imaging endpoints, importantly, these findings predicted the negative results of the large-scale clinical outcome trials. The effects of the proprotein convertase subtilisin-kexin

---

**Figure 3** Effect of statins on T1-weighted MRI high-intensity plaques. (A) Graph showing significant reduction in T1-weighted MRI signal intensity in a study of 48 patients with coronary artery disease treated with high-intensity pivastatin compared with the propensity matched control group of patients with coronary disease not treated with statins; (b) representative image of a high-intensity proximal left anterior descending coronary artery plaque identified in this study using T1-weighted MRI, with (c) reduction in signal intensity after statin treatment; CTCA imaging of the same artery showing low-attenuation plaque and positive remodelling in the area of high-intensity on MRI (C) before and (E) after statin therapy showing reduction in plaque volume. Figure adapted from Noguchi et al. J Am Coll Cardiol 2015. CTCA, CT coronary angiography.
9 (PCSK9) inhibitor evolocumab on coronary atherosclerosis has also been studied using imaging. Among other effects on cholesterol, niacin acts primarily by increasing HDL-c by 20%. A meta-analysis of trials performed before statins became standard of care showed significant benefit on clinical outcomes and imaging biomarkers, including carotid IMT. High-dose modified release niacin also showed slight reductions in carotid artery wall area measured by MRI in statin-treated patients in the Oxford Niaspan study, as well as significant reduction in carotid IMT in patients without diabetes in the Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) study, and in the ARBITER 6-HALTS (HDL and LDL treatment strategies) study with greater effect than ezetimibe. However, in the National Institute on Aging plaque study addition of niacin to statins did not reduce carotid wall volume assessed by MRI; a finding that echoes contemporary clinical outcome data showing no added clinical benefit for niacin in patients treated with statins and ezetimibe.

CETP inhibitors also act primarily by raising HDL-c. Torcetrapib is a CETP inhibitor that was withdrawn from the market due to concerns about off-target toxicity leading to raised systolic blood pressure and increased cardiovascular events. In the Investigation of Lipid Level Management Using Coronary Ultrasound to Assess Reduction in Coronary Atherosclerosis by CETP inhibition and HDL elevation study of 1188 patients with coronary artery disease imaged using serial IVUS, the addition of torcetrapib to atorvastatin did not significantly change the percent atheroma volume compared with atorvastatin monotherapy. The Rating Atherosclerotic Disease Change by Imaging with a New CETP Inhibitor-1 (RADIANCE-1) and RADIANCE-2 studies also showed that torcetrapib did not reduce progression of carotid IMT in patients with familial hypercholesterolaemia and mixed lipidemia. Similarly, dalcetrapib showed only nominal reduction in arterial 18F-FDG PET signals and carotid wall area, and no change in vascular calcification, in the Safety and efficacy of dalcetrapib on atherosclerotic disease
using novel non-invasive multimodality imaging (Dal-PLAQUE) study. Dalcetrapib also failed to improve clinical outcomes in the Effects of Dalcetrapib in Patients with a Recent Acute Coronary Syndrome (Dal-OUTCOMES) study, which was terminated early for futility (figure 5).73–75

PCSK9 inhibitors are human monoclonal antibodies that inactivate the enzyme PCSK9, preventing LDL-receptor degradation and reducing serum LDL-c by increasing its uptake into hepatocytes. In the randomised placebo-controlled Global Assessment of Plaque Regression with a PCSK9 Antibody as Measured by Intravascular Ultrasound (GLAGOV) trial that included data from 968 patients with coronary artery disease undergoing coronary angiography in 197 hospitals, the PCSK9 inhibitor evolocumab resulted in a modest −1% reduction in plaque volume measured by IVUS (figure 6).76 Similarly, in a Cochrane review of clinical outcome trials evaluating PCSK9 inhibitors, a modest <1% reduction in cardiovascular events was demonstrated, despite a marked −54% reduction in LDL-c compared with placebo.77 Results of the GLAGOV VH substudy, presented at the 2017 European Society of Cardiology Congress, showed that the addition of evolocumab to statin therapy did not significantly alter plaque composition measured by VH-IVUS (calcific, fibrofatty, fibrous or necrotic core volume), when compared with placebo.78

These modest effects coupled with little or no effect on all-cause mortality when applied to unselected patient cohorts,77 makes it difficult to justify the widespread use of expensive PCSK9 inhibitors. Indeed, the annual cost of a PCSK9 inhibitor (~$14 350) does not meet generally acceptable incremental cost-effectiveness thresholds.79 However, it is likely that higher risk cohorts would gain greater absolute clinical benefit, highlighting a potential role for imaging and other biomarkers to select those patients most likely to respond to treatment.80 Importantly, the Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk trial showed a significant reduction in cardiovascular events compared with placebo (9.8% vs 11.3%, p<0.001) in patients with atherosclerotic cardiovascular disease and raised LDL ≥1.8 mmol/L despite statin therapy.81 The ongoing A RaNdomized Double-blind Placebo ConTrolled Study Characterizing The Effects of PCSK9 Inhibition On Arterial Wall Inflammation in Patients With Elevated Lp(a), NCT02729025 study will determine whether evolocumab can reduce arterial inflammation measured by 18F-FDG PET in a cohort of patients with raised Lp(a) and LDL-c at baseline.

**Anti-inflammatory drugs**

For decades now, we have known that atherosclerosis is an inflammatory condition and not merely a disease of lipid dysregulation. Local and systemic inflammatory networks fuel every stage of the disease process from initial lesion formation, to the progression, destabilisation, rupture and healing of advanced atherosclerotic plaques.82 Accordingly, a new wave of anti-inflammatory therapies are in development for the management of atherosclerosis targeted to a range proinflammatory pathways and mediators. In several instances, imaging has proven useful as an early marker of drug efficacy, or lack thereof, and again, it holds promise in identifying the patients most likely to benefit from these expensive or potentially toxic treatments.

**Drugs used in systemic inflammatory diseases**

Several disease-modifying and biological agents currently used for the treatment of chronic inflammatory diseases might be useful for treatment of atherosclerosis, including methotrexate, colchicine, tumour necrosis factor-α (TNFα) inhibitors and rituximab. Intriguingly, in a prospective controlled study of patients with severe psoriasis treated with anti-TNFα therapies or the interleukin (IL)-12/IL-13 inhibitor ustekinumab, these anti-inflammatory therapies halted progression of CAC score but not luminal narrowing assessed by CTCA over a 13-month period.83 Anti-TNFα therapy has also been shown to reduce arterial IMT in patients with psoriasis who did not have calcified atherosclerotic plaques84 and reduce aortic 18F-FDG inflammatory signals in patients with rheumatoid arthritis.85 In another study of 55 women with rheumatoid arthritis and without overt cardiovascular disease who were treated with rituximab, a monoclonal antibody to CD20 on B cells, a significant 9% reduction in carotid IMT was seen in those patients whose arthritis also responded to treatment.86 A prospective study of rituximab in patients with ST elevation MI is ongoing (NCT03072199).

**Novel anti-inflammatory drugs for atherosclerosis**

Among the many emerging therapies being evaluated for the treatment of atherosclerosis with anti-inflammatory actions include drugs targeted at p38 mitogen-activated protein kinase (MAPK), lipoprotein-associated phospholipase A₁ (Lp-PLA₁) and IL-1β. p38 MAPK is a proinflammatory stress-activated kinase present in macrophages, endothelial and myocardiocytes, which among other mechanisms contributes to the amplification of the inflammatory cascade by promoting the release of cytokines, such as TNFα, IL-1 and IL-6. In a randomised placebo-controlled trial, the effects of the p38 MAPK inhibitor losmapimod on arterial inflammation were evaluated using 18F-FDG PET imaging in 99 patients with atherosclerosis who were also treated with statins.87 In this study, there was no significant difference detected in the primary endpoint of generalised vascular 18F-FDG uptake, although losmapimod did dampen 18F-FDG uptake in the most actively inflamed regions.87 In a subsequent clinical outcome trial including ~22 000 patients with acute MI, this drug did not significantly reduce the risk of major ischaemic cardiovascular events compared with placebo during the 12-week follow-up.88 In a study of another p38 MAPK inhibitor, BMS-582949, carotid and aortic 18F-FDG inflammatory signals were also not
significantly lowered by this drug in patients with stable atherosclerosis receiving low-dose statins.89

Lipoprotein-associated phospholipase A2 (Lp-PLA2) is another pharmacotherapeutic target that has been tested in cardiovascular disease. Increased Lp-PLA2 activity is associated with greater cardiovascular risk90 and, in preclinical studies, Lp-PLA2 inhibition has been shown to exert plaque stabilising effects mediated via anti-inflammatory actions on multiple genes associated with macrophage and T lymphocyte functioning.91 However, in a randomised placebo-controlled study of 83 patients with stable atherosclerosis imaged using 18F-FDG PET, the Lp-PLA2 inhibitor rilapladib showed no significant difference in the primary and secondary imaging end-points comparing vascular inflammation between treatment groups.92 Similarly, in another study, the Lp-PLA2 inhibitor darapladib failed to reduce coronary atheroma deformability (a marker of mechanical cap stress and plaque vulnerability) using IVUS palpography but did halt necrotic core expansion compared with placebo.93 Darapladib also did not significantly reduce the risk of MI, stroke or death in a randomised placebo-controlled trial of 15 828 patients with stable coronary disease followed up for 3.7 years.94 nor did it reduce major coronary events in a randomised, placebo-controlled trial of 13 026 patients followed up for 2.5 years after an acute coronary syndrome.95

Canakinumab is a human monoclonal antibody that inhibits IL-1β, a cytokine central to the acute inflammatory response that drives the classical IL-6 pathway. In a study of 189 individuals with atherosclerosis and type 2 diabetes mellitus or impaired glucose tolerance, there was no significant difference in mean carotid wall area on MRI observed after 12 months of drug treatment compared with placebo, despite measureable effects on hsCRP and IL-6.96 However, in a clinical outcome trial including 10 061 patients with previous history of MI and hsCRP >2 mg/L treated with canakinumab in addition to usual therapy, there was a significantly lower incidence of recurrent cardiovascular events compared with placebo.97 Further work is needed to fully evaluate the role of this, and other, anti-inflammatory drugs for the treatment of atherosclerosis.

Figure 5 Use of surrogate imaging markers to evaluate dalcetrapib. Graphs showing nominal changes in (A) arterial 18F-FDG inflammatory signals (7% reduction, p=0.08) in the most inflamed regions and (B) carotid total vessel area (4 mm² reduction; p=0.04) in a double-blind multicentre trial of 130 patients randomised to treatment with the cholesteryl ester transfer protein inhibitor dalcetrapib (green dots) versus placebo (red dots). In a substudy of the same trial, (C) the difference in carotid 18F-FDG signal intensity between dalcetrapib (blue dots) and placebo (red squares) was more apparent in patients without carotid calcification (p<0.001). However, lack of data showing a clear, consistent effect of dalcetrapib on these surrogate imaging markers predicted its inability to reduce recurrent cardiovascular events in patients with acute coronary syndrome in a large clinical outcome trial; (D) graph showing similar rates of cardiovascular events for dalcetrapib versus placebo in this study. Figure adapted from Fayad et al. Lancet 2011 (A and B);93 Joshi et al. J Am Coll Cardiol 2016 (C);94 Schwartz et al. N Eng J Med 2012 (D).95 MDS TBR, Most Diseased Segment Target-to-Background Ratio.
CONCLUSION
While we have many imaging strategies that can be applied as surrogate markers of drug efficacy, none of these methods can surpass the benchmark of a clinical outcome trial. However, imaging can be used to elucidate mechanisms of action and directly quantify specific drug effects on the arterial wall and atherosclerotic plaques. As we begin to see the clinical introduction of a range of novel antiatherosclerosis therapies to treat the many patients with so-called residual lipid or inflammatory burden, imaging can be used to help fast-track those drugs most likely to have a real clinical impact into large-scale phase III trials and to avoid wasting vast resources on drugs that have no measurable effect on any of the established markers of disease severity.

Acknowledgements  JMT is supported by the Wellcome Trust and the National Institute for Health Research. MRD is supported by the British Heart Foundation. JHFR is supported by the British Heart Foundation, Wellcome Trust, National Institute for Health Research Cambridge Biomedical Research Centre, Higher Education Funding Council for England and the Engineering and Physical Sciences Research Council.

Contributors  JMT wrote and edited the article. MRD and JHFR reviewed and edited the article.

Funding  The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests  None declared.

Patient consent  Not required.

Provenance and peer review  Commissioned; externally peer reviewed.

Author note  References which include a * are considered to be key references.

Open access  This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given and indication any change to the work is provided.

Key messages
► The use of imaging in clinical cardiovascular drug trials can impart valuable insights into underlying mechanisms of action and early evidence of drug efficacy to improve the efficiency of subsequent clinical outcome studies.
► Measurements of plaque burden are among the most useful surrogate imaging markers in cardiovascular disease, as this marker exhibits the strongest relationship with hard clinical outcomes.
► However, as modest changes in plaque burden occurring in response to lipid-lowering therapy do not match the large reductions in clinical outcomes observed in randomised trials, other mechanisms related to plaque composition and inflammation should also be considered for use as surrogate endpoints.
► Imaging endpoints cannot replace the need for large-scale clinical outcome studies to evaluate the true clinical value and safety of a new drug.
► Imaging studies have demonstrated that statins can dampen arterial inflammation, induce plaque regression and exert stabilising effects on plaque morphology and the degree of coronary macrocalcification.
► Imaging has also been used to test the effects of other cholesterol-modifying therapies, as well as anti-inflammatory therapies, on the arterial wall and atherosclerotic plaques.
given, and indication of whether changes were made. See: https://creativecommons.org/licenses/by/4.0/.

REFERENCES

1. Tarkin JM, Dweck MR, Evans NR, et al. Imaging atherosclerosis. Circ Res 2016;118:750–69.
2. Tarkin JM, Joshi FR, Rudd JH. PET imaging of inflammation in atherosclerosis. Nat Rev Cardiol 2014;11:443–57.
3. Figueroa AL, Aabbelaby A, Truong QA, et al. Measurement of arterial activity on routine FDG PET/CT images predicts risk of future CV events. JACC Cardiovasc Imaging 2013;6:1250–9.
4. Moon SH, Cho YS, Noh TS, et al. Carotid FDG uptake improves prediction of future cardiovascular events in asymptomatic individuals. JACC Cardiovasc Imaging 2015;8:949–56.
5. Bots ML, Hoes AW, Koudstaal PJ, et al. Common carotid intima-media thickness and risk of stroke and myocardial infarction: the Rotterdam Study. Circulation 1997;96:1432–7.
6. O’Leary DH, Polak JF, Kronmal RA, et al. Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular Health Study Collaborative Research Group. N Engl J Med 1999;340:14–22.
7. Lorenz MW, Polak JF, Kavoussi M, et al. Carotid intima-media thickness progression to predict cardiovascular events in the general population (the PRO-IMT collaborative project); a meta-analysis of individual participant data. Lancet 2012;379:2053–62.
8. Ferreira JP, Girend N, Bozek E, et al. Intima-media thickness is linearly and continuously associated with systolic blood pressure in a population-based cohort (STANISLAS Cohort Study). J Am Heart Assoc 2016;5.
9. Baber U, Mehran R, Sartori S, et al. Prevalence, impact, and predictive value of detecting subclinical coronary and carotid atherosclerosis in asymptomatic adults: the Bioline study. J Am Coll Cardiol 2015;65:1065–74.
10. Stone GW, Maehara A, Lansky AJ, et al. A prospective natural-history study of coronary atherosclerosis. N Engl J Med 2011;364:226–35.
11. Calvert P, Horgan RDR, O’Sullivan M, et al. Association between IVUS findings and adverse outcomes in patients with coronary artery disease: the VIVA (VH-IVUS in Vulnerable Atherosclerosis) Study. JACC Cardiovasc Imaging 2011;4:894–901.
12. Motoyama S, Itó H, Saino M, et al. Plaque characterization by coronary computed tomography angiography and the likelihood of acute coronary events in mid-term follow-up. J Am Coll Cardiol 2015;66:337–46.
13. Arab-Zadeh A, Fuster V. The myth of the “vulnerable plaque”: transitioning from a focus on individual lesions to atherosclerotic disease burden for coronary artery disease risk assessment. J Am Coll Cardiol 2015;65:846–55.
14. Kubo T, Maehara A, Mintz GS, et al. The dynamic nature of coronary artery disease burden for coronary artery disease risk assessment. J Am Coll Cardiol 2010;55:1590–7.
15. Alkhali M, Biasiolli L, Chai JT, et al. Quantification of carotid plaque lipid content with magnetic resonance T2 mapping in patients undergoing carotid endarterectomy. PLoS One 2017;12:e0181668–12.
16. Antontsoopoulos AS, Sanna F, Sabhanwal N, et al. Detecting human coronary inflammation by imaging peripheral fat. Sci Transl Med 2017;9:eaa2658.
17. van Nuenen LX, Zimmermann FM, Tonio PA, et al. Fractional flow reserve versus angiography for guidance of PCI in patients with multivessel coronary artery disease (FAME): 5-year follow-up of a randomised controlled trial. Lancet 2015;386:1853–60.
18. Detrano R, Guerci AD, Carr JJ, et al. Coronary calcium as a predictor of coronary events in four racial or ethnic groups. N Engl J Med 2008;358:1336–45.
19. Libby P. How does lipid lowering prevent coronary events? New insights from human imaging trials. Eur Heart J 2015;36:472–2.
20. Sobel BE, Furberg CD. Surrogates, semantics, and sensible public policy. Circulation 1997;95:1661–3.
21. Nichols SJ, Ballantyne CM, Barter PJ, et al. Effect of two intensive statin regimens on progression of coronary disease. N Engl J Med 2011;365:2078–87.
22. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the scandinavian simvastatin survival study (4S). Lancet 1994;344:1383–9.
23. LaRosa JC, Grundy SM, Waters DD, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005;352:1425–35.
24. Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004;350:1495–504.
25. Bainteng C, Blackwell L, Emerson J, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010;376:1670–81.
26. Tiwakar A, Faday ZA, Mogh R, et al. Intensification of statin therapy results in a rapid reduction in atherosclerotic inflammation: results of a multicenter fluorodeoxyglucose–positron emission tomography/computed tomography feasibility study. J Am Coll Cardiol 2013;62:909–17.
27. Tahara N, Kai H, Ishibashi M, et al. Simvastatin attenuates plaque inflammation. J Am Coll Cardiol 2006;48:1825–31.
28. Wu YW, Kao HL, Huang CL, et al. The effects of 3-month atorvastatin therapy on arterial inflammation, calcification, abdominal adipose tissue and circulating biomarkers. Eur J Nucl Med Mol Imaging 2012;39:399–407.
29. Tang TY, Howarth SP, Miller SR, et al. The ATHROMA (atorvastatin therapy: effects on reduction of macrophage activity) study. J Am Coll Cardiol 2009;53:2039–50.
30. de Groot E, Jukema JW, Montauban van Swijndregt AD, et al. B-mode ultrasound assessment of plaque composition: comparison of carotid and femoral artery walls and its correlation with coronary arteriographic findings: a report of the Regression Growth Evaluation Study (REGRESS). J Am Coll Cardiol 1998;31:1561–7.
31. Crouse JR, Raichlen JS, Riley WA, et al. Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: the METEOR Trial. JAMA 2007;297:1344–53.
32. Corti R, Faday ZA, Fuster V, et al. Effects of lipid-lowering by simvastatin on human atherosclerotic lesions: a longitudinal study by high-resolution, noninvasive magnetic resonance imaging. Circulation 2001;104:2498–502.
33. Corti R, Fuster V, Faday ZA, et al. Effects of aggressive versus conventional lipid-lowering therapy by simvastatin on human atherosclerotic lesions: a prospective, randomized, double-blind trial with high-resolution magnetic resonance imaging. J Am Coll Cardiol 2005;46:106–12.
34. Nissen SE, Newby SL, Sipahi I, et al. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA 2006;295:1556–65.
35. Nissen SE, Tuzcu EM, Schoenhagen P, et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA 2004;291:1171–80.
36. Okazaki S, Yokoyama T, Miyachi K, et al. Early statin treatment in patients with acute coronary syndrome: demonstration of the beneficial effect on atherosclerotic lesions by serial volumetric intravascular ultrasound analysis during half a
year after coronary event: the ESTABLISH Study. Circulation 2004;110:1061–8.

37 Räber L, Tanimaki M, Zauw S, et al. Effect of high-intensity statin therapy on atherosclerosis in non-infarct-related coronary arteries (IBIS-4): a serial intravascular ultrasound study. Eur Heart J 2015;36:490–500.

38 Katoaka Y, Wolski K, Balog C, et al. Progression of coronary atherosclerosis in stable patients with ultrasonic features of high-risk plaques. Eur Heart J Cardiovasc Imaging 2014;15:1035–41.

39 Zhao XQ, Dong L, Hatsukami T, et al. MRI imaging of carotid plaque composition during lipid-lowering therapy: a prospective assessment of effect and time course. JACC Cardiovasc Imaging 2011;4:977–86.

40 Underhill HR, Yuan C, Zhao XQ, et al. Effect of rosuvastatin therapy on carotid plaque morphology and composition in moderately hypercholesterolemic patients: a high-resolution magnetic resonance imaging trial. Am Heart J 2008;155:584, e1–584.e8.

41 Yogo M, Sasaki M, Ayaoi M, et al. Intensive lipid lowering therapy with titrated rosuvastatin yields greater atherosclerotic aortic plaque regression: Serial magnetic resonance imaging observations from RAPID study. Atherosclerosis 2014;232:31–9.

42 Park SJ, Kang SJ, Ahn JM, et al. Effect of statin treatment on modifying plaque composition: a double-blind, randomized study. J Am Coll Cardiol 2013;62:1772–83.

43 Kwon O, Kang SJ, Kang SH, et al. Relationship between serum inflammatory marker levels and the dynamic changes in coronary plaque characteristics after statin therapy. Circ Cardiovasc Imaging 2017;10:e005934.

44 Komukai K, Kubo T, Kitabata H, et al. Effect of atorvastatin therapy on fibrous cap thickness in coronary plaque as assessed by optical coherence tomography: the EASY-FIT study. J Am Coll Cardiol 2014;64:2207–17.

45 Katoaka Y, Puri R, Hammadah M, et al. Frequency-domain optical coherence tomographic analysis of plaque microstructures at nonruptured small plaque in patients receiving potent statin therapy. J Am Coll Cardiol 2014;64:2207–17.

46 Hsu J, Xing L, Jia H, et al. Comparison of intensive versus moderate lipid-lowering therapy on fibrous cap and atheroma volume of coronary lipid-rich plaque using serial optical coherence tomography and intravascular ultrasound imaging. Am J Cardiol 2016;117:800–6.

47 Kini AS, Baber U, Kovacic JC, et al. Changes in plaque lipid content after short-term intensive versus standard statin therapy: the YELLOW trial (reduction in yellow plaque by aggressive lipid-lowering therapy). J Am Coll Cardiol 2013;62:21–9.

48 MAAS Investigators. Effect of simvastatin on coronary atheroma: the Multicentre Anti-Atheroma Study (MAAS). The Lancet 1994;344:633–8.

49 Ballantyne CM, Raichlen JS, Nicholas SJ, et al. Effect of rosuvastatin therapy on coronary artery stenoses assessed by quantitative coronary angiography: a study to evaluate the effect of rosuvastatin on intracoronary ultrasound-derived coronary atheroma burden. Circulation 2008;117:2488–66.

50 Insue K, Motoyama S, Sarai M, et al. Serial coronary CT angiography-verified changes in plaque characteristics as an end point: evaluation of effect of statin intervention. JACC Cardiovasc Imaging 2010;3:691–8.

51 Zieb I, Li D, Nasir K, et al. Effect of statin treatment on coronary plaque progression - a serial coronary CT angiography study. Atherosclerosis 2012;213:196–204.

52 Negociu T, Tanaka A, Kawasaki T, et al. Effect of intensive statin therapy on coronary high-intensity plaques detected by noncontrast 11-weighted imaging: the aquamarine pilot study. J Am Coll Cardiol 2015;66:245–56.

53 Schmermund A, Achenbach S, Budde T, et al. Effect of intensive versus standard lipid-lowering treatment with atorvastatin on the progression of calcified coronary atherosclerosis over 12 months: a multicenter, randomized, double-blind trial. Circulation 2006;113:427–37.

54 Auscher S, Heinsen L, Nieman K, et al. Effects of intensive lipid-lowering therapy on coronary plaques composition in patients with acute myocardial infarction: Assessment with serial coronary CT angiography. Atherosclerosis 2015;241:579–87.

55 Puri R, Nicholas SJ, Shao M, et al. Impact of statins on serial coronary calcification during atheroma progression and regression. J Am Coll Cardiol 2015;65:1273–82.

56 Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med 2015;372:2387–97.

57 Kastelein JJP, Akdim F, Stroes ESG, et al. Simvastatin with or without ezetimibe in familial hypercholesterolaemia. N Engl J Med 2008;358:1431–40.

58 Fleg JL, Mete M, Howard BV, et al. Effect of statins alone versus statins plus ezetimibe on carotid atherosclerosis in type 2 diabetes: the SANDS (Stop Atherosclerosis in Native Diabetics Study) trial. J Am Coll Cardiol 2008;52:2199–205.

59 Tsuji K, Sugiyama S, Sumida H, et al. Impact of dual lipid-lowering strategy with ezetimibe and atorvastatin on coronary plaque regression in patients with percutaneous coronary intervention: The multicenter randomizedcontrolled PRECISE-VUS Trial. J Am Coll Cardiol 2015;66:495–507.

60 Habara M, Nasu K, Terashima M, et al. Impact on optical coherence tomographic coronary findings of fluvastatin alone versus fluvastatin plus ezetimibe. Am J Cardiol 2014;113:580–7.

61 Kourakis I, Mitzt GS, Skalicky H, et al. Virtual histology evaluation of atherosclerosis regression during atorvastatin and ezetimibe administration: HEAVEN study. Circ J 2012;76:176–83.

62 Ueda Y, Hiro T, Hirayama A, et al. ZIPANGU Investigators. Effect of Ezetimbe on Stabilization and Regression of Intracoronary Plaque - The ZIPANGU Study. Circ J 2017;81:1611–9.

63 Bruckert E, Labbreuche J, Amanace P. Meta-analysis of the effect of niocotic acid alone or in combination on cardiovascular events and atherosclerosis. Atherosclerosis 2010;210:353–61.

64 Lee JM, Robson MD, Yu LM, et al. Effects of high-dose modified-release nicotinic acid on atherosclerosis and vascular function: a randomized, placebo-controlled, magnetic resonance imaging study. J Am Coll Cardiol 2013;62:1787–94.

65 Taylor AL, Sullenger BE, Lee HJ, et al. Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation 2004;110:3512–7.

66 Sibley CT, Vavere AL, Gottlieb J, et al. MRI-measured regression of carotid atherosclerosis induced by statins with and without niacin in a randomised controlled trial: the NIA plaque study. Heart 2013;99:1675–80.

67 Boden WE, Probstfield JL, Anderson T, et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med 2011;365:2255–67.

68 Landray MJ, Haynes R, Hopevell JC, et al. Effects of extended-release niacin with laropiprant in high-risk patients. N Engl J Med 2014;371:203–12.

69 Barter PJ, Caulfield M, Eriksson M, et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 2007;357:210–22.

70 Nissen SE, Tardif JC, Nicholas SJ, et al. Effect of torcetrapib on the progression of coronary atherosclerosis. N Engl J Med 2007;356:1304–16.

71 Kastelein JJ, van Leuven SJ, Burgess L, et al. Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolaemia. N Engl J Med 2007;356:1620–30.

72 Bots ML, Visseren FL, Evans GW, et al. Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): a randomised, double-blind trial. Lancet 2007;370:153–60.

73 Fayad ZA, Mani V, Woodward M, et al. Safety and efficacy of dalcetrapib on atherosclerotic disease using novel non-invasive multimodality imaging (dal-PLAQIE): a randomised clinical trial. Lancet 2011;378:1547–59.

74 Joshi FR, Rajani NK, Abt M, et al. Does vascular calcification accelerate inflammation?: a substudy of the dal-PLAQIE Trial. J Am Coll Cardiol 2016;67:69–78.

75 Schwartz GG, Olson AG, Abt M, et al. Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med 2012;367:2089–99.

76 Nicholas SJ, Puri R, Anderson T, et al. Effect of Evolocumab on Progression of Coronary Disease in Statin-Treated Patients: The GLAGOV Randomized Clinical Trial. JAMA 2016;316:2373–84.

77 Schmitz AE, Pearce MS, Wilkins JT, et al. PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease. Cochrane Database Syst Rev 2017;4:CD011748.
78. Nicholls SJ, Kassahun H, Brennan DM, et al. Effect of the PCSK9 inhibitor, evolocumab, on the composition of coronary atherosclerosis: Insights from the GLAGOV trial. European Society of Cardiology 2017.

79. Kazi DS, Moran AE, Coxson PG, et al. Cost-effectiveness of PCSK9 inhibitor therapy in patients with heterogenous familial hypercholesterolemia or atherosclerotic cardiovascular disease. JAMA 2016;316:743–53.

80. Alkilani M, Chai JT, Choudhury RP. Plaque imaging to refine indications for emerging lipid-lowering drugs. Eur Heart J Cardiovasc Pharmacother 2017;3:58–67.

81. Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med 2016;376:1713–22.

82. Teague HL, Ahlman MA, Alavi A, et al. Unraveling vascular inflammation: from immunology to imaging. J Am Coll Cardiol 2017;70:1403–12.

83. Hjuler KF, Bøttcher M, Vestergaard C, et al. Association between changes in coronary artery disease progression and treatment with biologic agents for severe psoriasis. JAMA Dermatol 2016;152:1114–21.

84. Jókai H, Szakonyi J, Kontár O, et al. Impact of effective tumor necrosis factor-alfa inhibitor treatment on arterial intima-media thickness in patients with rheumatoid arthritis. J Am Coll Cardiol 2017;69:523–9.

85. Mäki-Petäjä KM, Elkhawad M, Cheriyan J, et al. Anti-tumor necrosis factor-α therapy reduces aortic inflammation and stiffness in patients with rheumatoid arthritis. Circulation 2012;126:2473–80.

86. Novikova DS, Popkova TV, Lukina GV, et al. The effects of rituximab on lipids, arterial stiffness and carotid intima-media thickness in rheumatoid arthritis. J Korean Med Sci 2016;31:202–7.

87. Elkhawad M, Rudd JH, Sarov-Blat L, et al. Effects of p38 mitogen-activated protein kinase inhibition on vascular and systemic inflammation in patients with atherosclerosis. JACC Cardiovasc Imaging 2012;5:911–22.

88. O’Donoghue ML, Glaser R, Cavender MA, et al. Effect of losmapimod on cardiovascular outcomes in patients hospitalized with acute myocardial infarction: a randomized clinical trial. JAMA 2016;315:1591–9.

89. Emami H, Vuic E, Subramanian S, et al. The effect of BMS-582949, a P38 mitogen-activated protein kinase (P38 MAPK) inhibitor on arterial inflammation: a multicenter FDG-PET trial. Atherosclerosis 2015;240:490–6.

90. Thompson A, Gao P, Orfei L, et al. Liprotein-associated phospholipase A2 and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies. Lancet 2010;375:1536–44.

91. Wilensky RL, Shi Y, Mohler ER, et al. Inhibition of lipoprotein-associated phospholipase A2 reduces complex coronary atherosclerotic plaque development. Nat Med 2008;14:1059–66.

92. Tawakol A, Singh P, Rudd JH, et al. Effect of treatment for 12 weeks with rilapladib, a lipoprotein-associated phospholipase A2 inhibitor, on arterial inflammation as assessed with 18F-fluorodeoxyglucose-positron emission tomography imaging. J Am Coll Cardiol 2014;63:86–8.

93. Serruys PW, Garcia-Garcia HM, Buszman P, et al. Effects of the direct lipoprotein-associated phospholipase A2 inhibitor darapladib on human coronary atherosclerotic plaque. Circulation 2008;118:1172–82.

94. White HD, Held C, Stewart R, et al. Darapladib for preventing ischemic events in stable coronary heart disease. N Engl J Med 2014;370:1702–11.

95. O’Donoghue ML, Braunwald E, White HD, et al. Effect of darapladib on major coronary events after an acute coronary syndrome: the SOLID-TIMI 52 randomized clinical trial. JAMA 2014;312:1006–15.

96. Choudhury RP, Birks JS, Mani V, et al. Arterial effects of canakinumab in patients with atherosclerosis and type 2 diabetes or glucose intolerance. J Am Coll Cardiol 2016;68:1769–80.

97. Ridker PM, Everett BM, Thuren T, et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med 2017;377:1119–31.